

Charles Marie Dumontet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8078973/publications.pdf>

Version: 2024-02-01

273
papers

19,950
citations

16411

64
h-index

12233

133
g-index

285
all docs

285
docs citations

285
times ranked

24546
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Strategies and challenges for the next generation of antibody-drug conjugates. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 315-337. | 21.5 | 1,527 |
| 2 | Microtubule-binding agents: a dynamic field of cancer therapeutics. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 790-803. | 21.5 | 1,431 |
| 3 | Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1782-1791. | 13.9 | 1,022 |
| 4 | Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 447-464. | 21.5 | 925 |
| 5 | Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. <i>Blood</i> , 2007, 109, 3489-3495. | 0.6 | 845 |
| 6 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , 2006, 108, 3289-3294. | 0.6 | 639 |
| 7 | Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death. <i>Journal of Clinical Oncology</i> , 1999, 17, 1061-1061. | 0.8 | 524 |
| 8 | Nucleoside analogues and nucleobases in cancer treatment. <i>Lancet Oncology</i> , The, 2002, 3, 415-424. | 5.1 | 494 |
| 9 | Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. <i>Blood</i> , 2000, 95, 802-806. | 0.6 | 484 |
| 10 | Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 1168-1176. | 0.8 | 461 |
| 11 | The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6956-6961. | 3.2 | 360 |
| 12 | Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2031-2042. | 1.9 | 301 |
| 13 | Is class III β -tubulin a predictive factor in patients receiving tubulin-binding agents?. <i>Lancet Oncology</i> , The, 2008, 9, 168-175. | 5.1 | 275 |
| 14 | SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 4574-4583. | 3.2 | 258 |
| 15 | Class III β -tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 2001-2007. | 1.9 | 224 |
| 16 | Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. <i>Gastroenterology</i> , 2012, 143, 664-674.e6. | 0.6 | 218 |
| 17 | Antibody-Drug Conjugates: The Last Decade. <i>Pharmaceuticals</i> , 2020, 13, 245. | 1.7 | 207 |
| 18 | Dysregulation of Ribosome Biogenesis and Translational Capacity Is Associated with Tumor Progression of Human Breast Cancer Cells. <i>PLoS ONE</i> , 2009, 4, e7147. | 1.1 | 198 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Expression of Class III β -Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 5481-5486. | 3.2 | 193 |
| 20 | High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Blood</i> , 1998, 91, 3148-3155. | 0.6 | 186 |
| 21 | Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure-Activity Relationship. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2307-2310. | 2.9 | 166 |
| 22 | Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. <i>Medicinal Research Reviews</i> , 2002, 22, 512-529. | 5.0 | 158 |
| 23 | Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2780-2790. | 1.9 | 152 |
| 24 | Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 41-47. | 2.1 | 148 |
| 25 | The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. <i>Lancet Oncology</i> , 2011, 12, 693-702. | 5.1 | 147 |
| 26 | Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. <i>British Journal of Haematology</i> , 1998, 103, 235-241. | 1.2 | 144 |
| 27 | In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2002, 117, 860-868. | 1.2 | 144 |
| 28 | Class III β -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10. <i>Clinical Cancer Research</i> , 2007, 13, 994-999. | 3.2 | 138 |
| 29 | The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. <i>Cancer</i> , 2007, 109, 292-299. | 2.0 | 136 |
| 30 | The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. <i>Oncotarget</i> , 2017, 8, 57622-57641. | 0.8 | 135 |
| 31 | Chemoresistance in Non-Small Cell Lung Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2005, 5, 73-88. | 7.0 | 129 |
| 32 | Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. <i>British Journal of Haematology</i> , 1999, 106, 78-85. | 1.2 | 125 |
| 33 | Potential mechanisms of resistance to cytarabine in AML patients. <i>Leukemia Research</i> , 2002, 26, 621-629. | 0.4 | 125 |
| 34 | Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 178-185. | 1.9 | 125 |
| 35 | Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. <i>International Journal of Cancer</i> , 2010, 126, 545-562. | 2.3 | 110 |
| 36 | Ixabepilone: targeting β -tubulin expression in taxane-resistant malignancies. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 17-25. | 1.9 | 109 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | C-Isoprenylation of Flavonoids Enhances Binding Affinity toward P-Glycoprotein and Modulation of Cancer Cell Chemoresistance. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 763-768. | 2.9 | 108 |
| 38 | Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. <i>Investigational New Drugs</i> , 2012, 30, 1121-1131. | 1.2 | 105 |
| 39 | Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. <i>Cancer</i> , 2006, 107, 2698-2705. | 2.0 | 100 |
| 40 | Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 335-341. | 0.5 | 96 |
| 41 | The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. <i>Frontiers in Immunology</i> , 2018, 9, 2100. | 2.2 | 94 |
| 42 | Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. <i>Breast Cancer Research</i> , 2015, 17, 57. | 2.2 | 93 |
| 43 | Alteration of Natural Killer cell phenotype and function in obese individuals. <i>Clinical Immunology</i> , 2017, 177, 12-17. | 1.4 | 93 |
| 44 | Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP). <i>Breast Cancer Research</i> , 2019, 21, 7. | 2.2 | 93 |
| 45 | Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. <i>International Journal of Cancer</i> , 2002, 97, 439-445. | 2.3 | 92 |
| 46 | Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 113, 772-778. | 1.2 | 90 |
| 47 | Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , 2019, 154, 21-31. | 1.9 | 89 |
| 48 | Jatrophane Diterpenes as Modulators of Multidrug Resistance. Advances of Structure-Activity Relationships and Discovery of the Potent Lead Pepluanin A. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 988-992. | 2.9 | 87 |
| 49 | Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. <i>British Journal of Haematology</i> , 2003, 122, 53-60. | 1.2 | 83 |
| 50 | Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 708-715. | 0.6 | 81 |
| 51 | Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdrl Gene Activation by the Cyclosporin PSC 833. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1593-1602. | 3.0 | 80 |
| 52 | Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 1922-1926. | 0.6 | 80 |
| 53 | Small Molecule Inhibitors of ERCC1-XPF Protein-Protein Interaction Synergize Alkylating Agents in Cancer Cells. <i>Molecular Pharmacology</i> , 2013, 84, 12-24. | 1.0 | 80 |
| 54 | Jatrophane Diterpenes as P-Glycoprotein Inhibitors. First Insights of Structure-Activity Relationships and Discovery of a New, Powerful Lead. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3395-3402. | 2.9 | 79 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. <i>Genes To Cells</i> , 2002, 7, 29-39. | 0.5 | 76 |
| 56 | Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins. <i>Journal of Biological Chemistry</i> , 1997, 272, 5974-5982. | 1.6 | 74 |
| 57 | Microtubule-Associated Parameters as Predictive Markers of Docetaxel Activity in Advanced Breast Cancer Patients: Results of a Pilot Study. <i>Clinical Breast Cancer</i> , 2002, 3, 341-345. | 1.1 | 74 |
| 58 | The role of β III tubulin in predicting chemoresistance in non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 67, 136-143. | 0.9 | 71 |
| 59 | Thalidomide in patients with advanced multiple myeloma: a study of 83 patientsâ€“report of the intergroupe francophone du myÃ©lome (IFM). <i>The Hematology Journal</i> , 2002, 3, 185-192. | 2.0 | 71 |
| 60 | Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. <i>Blood</i> , 2005, 105, 767-774. | 0.6 | 70 |
| 61 | Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. <i>American Journal of Medicine</i> , 1990, 88, 13-20. | 0.6 | 67 |
| 62 | Pharmacological Inhibition of LIM Kinase Stabilizes Microtubules and Inhibits Neoplastic Growth. <i>Cancer Research</i> , 2012, 72, 4429-4439. | 0.4 | 67 |
| 63 | mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and geneâ€™expression levels. <i>Cancer Science</i> , 2008, 99, 1992-2003. | 1.7 | 66 |
| 64 | Antimitotic Activity of 5-Hydroxy-7-methoxy-2-phenyl-4-quinolones. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4964-4970. | 2.9 | 65 |
| 65 | Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. <i>Journal of Molecular Endocrinology</i> , 2009, 42, 87-103. | 1.1 | 65 |
| 66 | Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3831-3840. | 1.2 | 65 |
| 67 | Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. <i>BMC Pharmacology</i> , 2004, 4, 8. | 0.4 | 62 |
| 68 | cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 363-370. | 0.9 | 62 |
| 69 | Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line. <i>Clinical Cancer Research</i> , 2004, 10, 5614-5621. | 3.2 | 60 |
| 70 | Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1123-1132. | 0.6 | 60 |
| 71 | A revised nomenclature for the human and rodent β -tubulin gene family. <i>Genomics</i> , 2007, 90, 285-289. | 1.3 | 60 |
| 72 | Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction. <i>PLoS ONE</i> , 2012, 7, e51329. | 1.1 | 60 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III β -tubulin. <i>Journal of Cellular Physiology</i> , 2009, 221, 505-513. | 2.0 | 59 |
| 74 | Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. <i>Chemical Science</i> , 2019, 10, 4048-4053. | 3.7 | 59 |
| 75 | Class III β -Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4511-4516. | 3.2 | 58 |
| 76 | A New P-Glycoprotein Inhibitor from the Caper Spurge (<i>Euphorbia lathyris</i>). <i>Journal of Natural Products</i> , 2003, 66, 140-142. | 1.5 | 57 |
| 77 | Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1268-1276. | 1.9 | 57 |
| 78 | Germline Lysine-Specific Demethylase 1 (<i>LSD1/KDM1A</i>) Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018, 78, 2747-2759. | 0.4 | 56 |
| 79 | Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 6979-6987. | 1.4 | 54 |
| 80 | The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. <i>Nature Communications</i> , 2021, 12, 293. | 5.8 | 54 |
| 81 | A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413. | 3.3 | 53 |
| 82 | Pyrimidine nucleoside analogs in cancer treatment. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 717-728. | 1.1 | 51 |
| 83 | The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site. <i>Cancer</i> , 2006, 106, 2058-2066. | 2.0 | 51 |
| 84 | Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 1673-1676. | 0.6 | 51 |
| 85 | Early Diagnosis of Ventilator-Associated Pneumonia. <i>Chest</i> , 1996, 110, 1558-1565. | 0.4 | 49 |
| 86 | In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. <i>Blood</i> , 2003, 102, 1549-1550. | 0.6 | 49 |
| 87 | Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: A review. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1912-1928. | 1.2 | 49 |
| 88 | BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. <i>Blood</i> , 2008, 112, 3154-3163. | 0.6 | 47 |
| 89 | Understanding and circumventing resistance to anticancer monoclonal antibodies. <i>MAbs</i> , 2009, 1, 222-229. | 2.6 | 47 |
| 90 | Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1776, 138-159. | 3.3 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. <i>American Journal of Medicine</i> , 1999, 106, 191-197. | 0.6 | 45 |
| 92 | Class III β -tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 27-34. | 1.1 | 45 |
| 93 | Transfection of cells in suspension by ultrasound cavitation. <i>Journal of Controlled Release</i> , 2010, 142, 251-258. | 4.8 | 43 |
| 94 | Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2008, 112, 572-580. | 2.0 | 42 |
| 95 | Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 375, 308-314. | 1.0 | 42 |
| 96 | Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. <i>Bulletin Du Cancer</i> , 2005, 92, E25-30. | 0.6 | 42 |
| 97 | Expression of excision repair cross-complementation group 1 and class III β -tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 62, 105-112. | 0.9 | 40 |
| 98 | How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. <i>Frontiers in Immunology</i> , 2020, 11, 492. | 2.2 | 40 |
| 99 | Mechanisms of action and resistance to tubulin-binding agents. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 779-788. | 1.9 | 39 |
| 100 | Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. <i>Bone Marrow Transplantation</i> , 2010, 45, 1316-1324. | 1.3 | 38 |
| 101 | Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539. | 5.8 | 38 |
| 102 | A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 4350-4355. | 3.2 | 38 |
| 103 | Primary cutaneous marginal zone lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 156-162. | 2.0 | 37 |
| 104 | BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 3988-3997. | 3.2 | 37 |
| 105 | <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2422-2432. | 3.2 | 37 |
| 106 | Modified jatrophone diterpenes as modulators of multidrug resistance from <i>Euphorbia dendroides</i> L.. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 5221-5227. | 1.4 | 36 |
| 107 | <i>In vivo</i> Model of Follicular Lymphoma Resistant to Rituximab. <i>Clinical Cancer Research</i> , 2009, 15, 851-857. | 3.2 | 36 |
| 108 | Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. <i>Journal of Molecular Graphics and Modelling</i> , 2009, 28, 113-130. | 1.3 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Structure-Activity Relationships for Euphocharacins A - L, a New Series of Jatrophone Diterpenes, as Inhibitors of Cancer Cell P-Glycoprotein. <i>Planta Medica</i> , 2004, 70, 657-665. | 0.7 | 34 |
| 110 | Selective modulation of P-glycoprotein activity by steroidal saponines from <i>Paris polyphylla</i> . <i>FÄ-toterapÄ-Äç</i> , 2009, 80, 39-42. | 1.1 | 34 |
| 111 | Gemcitabine is active against clinical multiresistant <i>Staphylococcus aureus</i> strains and is synergistic with gentamicin. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 444-447. | 1.1 | 34 |
| 112 | Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 813-824. | 5.5 | 34 |
| 113 | The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. <i>Haematologica</i> , 2005, 90, 1699-701. | 1.7 | 34 |
| 114 | Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 547-554. | 1.1 | 33 |
| 115 | ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. <i>Experimental Cell Research</i> , 2007, 313, 473-485. | 1.2 | 33 |
| 116 | Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 2937-2944. | 1.2 | 33 |
| 117 | Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019, 33, 2324-2330. | 3.3 | 33 |
| 118 | Development of a sensitive and selective LC/MS/MS method for the simultaneous determination of intracellular 1-beta-d-arabinofuranosylcytosine triphosphate (araCTP), cytidine triphosphate (CTP) and deoxycytidine triphosphate (dCTP) in a human follicular lymphoma cell line. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1417-1425. | 1.2 | 32 |
| 119 | 3â€Arylâ€4â€methylâ€2â€quinolones Targeting Multiresistant <i>Staphylococcus aureus</i> Bacteria. <i>ChemMedChem</i> , 2013, 8, 652-657. | 1.6 | 32 |
| 120 | Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatographyâ€tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 2925-2941. | 1.9 | 32 |
| 121 | Thalidomide in patients with advanced multiple myeloma. <i>The Hematology Journal</i> , 2000, 1, 186-189. | 2.0 | 32 |
| 122 | Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. <i>Prostate</i> , 2013, 73, 1738-1746. | 1.2 | 31 |
| 123 | High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. <i>World Journal of Stem Cells</i> , 2017, 9, 227-234. | 1.3 | 31 |
| 124 | ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor Å expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. <i>Endocrine-Related Cancer</i> , 2008, 15, 125-138. | 1.6 | 30 |
| 125 | Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8. | 2.3 | 30 |
| 126 | Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. <i>PLoS Genetics</i> , 2018, 14, e1007111. | 1.5 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Differential expression of tubulin isotypes during the cell cycle. , 1996, 35, 49-58. | | 29 |
| 128 | Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001. <i>Leukemia and Lymphoma</i> , 2003, 44, 257-262. | 0.6 | 29 |
| 129 | Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL). <i>Leukemia and Lymphoma</i> , 2004, 45, 711-714. | 0.6 | 29 |
| 130 | Identification and characterization of inhibitors of cytoplasmic 5â€²-nucleotidase cN-II issued from virtual screening. <i>Biochemical Pharmacology</i> , 2013, 85, 497-506. | 2.0 | 29 |
| 131 | Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. <i>MAbs</i> , 2015, 7, 192-198. | 2.6 | 29 |
| 132 | The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide. <i>British Journal of Haematology</i> , 2001, 112, 405-409. | 1.2 | 28 |
| 133 | Role of IMP-SELECTIVE 5â€²-NUCLEOTIDASE (cN-II) in HEMATOLOGICAL MALIGNANCIES. <i>Leukemia and Lymphoma</i> , 2003, 44, 1105-1111. | 0.6 | 28 |
| 134 | Special feature of mixed phosphotriester derivatives of cytarabine. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6340-6347. | 1.4 | 28 |
| 135 | A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1890-1899. | 1.9 | 28 |
| 136 | Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1361-1365. | 0.8 | 27 |
| 137 | Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. <i>Cell Cycle</i> , 2008, 7, 3074-3082. | 1.3 | 27 |
| 138 | Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. <i>Pharmaceuticals</i> , 2021, 14, 247. | 1.7 | 27 |
| 139 | Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. <i>Oncogene</i> , 2004, 23, 2287-2297. | 2.6 | 26 |
| 140 | Potent and Fully Noncompetitive Peptidomimetic Inhibitor of Multidrug Resistance P-Glycoprotein. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6720-6729. | 2.9 | 26 |
| 141 | Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. <i>British Journal of Haematology</i> , 2002, 118, 210-217. | 1.2 | 25 |
| 142 | Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. <i>PLoS ONE</i> , 2017, 12, e0170160. | 1.1 | 25 |
| 143 | Acute Silicosis Due to Inhalation of a Domestic Product. <i>The American Review of Respiratory Disease</i> , 1991, 143, 880-882. | 2.9 | 24 |
| 144 | In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. <i>Biochemical Pharmacology</i> , 2003, 66, 2185-2191. | 2.0 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Hybrid Model of Erythropoiesis and Leukemia Treatment with Cytosine Arabinoside. <i>SIAM Journal on Applied Mathematics</i> , 2011, 71, 2246-2268. | 0.8 | 24 |
| 146 | Structural Insights into the Inhibition of Cytosolic 5â€²-Nucleotidase II (cN-II) by Ribonucleoside 5â€²-Monophosphate Analogues. <i>PLoS Computational Biology</i> , 2011, 7, e1002295. | 1.5 | 24 |
| 147 | CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1051-1055. | 2.6 | 24 |
| 148 | Nucleoside analogue delivery systems in cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2007, 4, 513-531. | 2.4 | 23 |
| 149 | Î²3â€²-Tubulin is induced by estradiol in human breast carcinoma cells through an estrogenâ€²receptor dependent pathway. <i>Cytoskeleton</i> , 2009, 66, 378-388. | 4.4 | 23 |
| 150 | Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells. <i>BMC Cancer</i> , 2010, 10, 135. | 1.1 | 23 |
| 151 | Influence of p53 and p21/WAF1 expression on sensitivity of cancer cells to cladribine. <i>Biochemical Pharmacology</i> , 2003, 65, 121-129. | 2.0 | 22 |
| 152 | Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 163-170. | 0.8 | 22 |
| 153 | Paclitaxel-Loaded Microparticles for Intratumoral Administration via the TMT Technique: Preparation, Characterization, and Preliminary Antitumoral Evaluation. <i>Drug Development and Industrial Pharmacy</i> , 2008, 34, 698-707. | 0.9 | 22 |
| 154 | ADP Ribosylation Factor Like 2 (Arl2) Regulates Breast Tumor Aggressivity in Immunodeficient Mice. <i>PLoS ONE</i> , 2009, 4, e7478. | 1.1 | 22 |
| 155 | Severe autoimmune cytopenias in treatment-naïve hepatitis C virus infection: clinical description of 16 cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 245-253. | 0.8 | 22 |
| 156 | Prognostic value of PINI index in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2012, 88, 306-313. | 1.1 | 22 |
| 157 | A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. <i>Frontiers in Immunology</i> , 2019, 10, 1943. | 2.2 | 22 |
| 158 | Structureâ€²activity relationships of Î²-hydroxyphosphonate nucleoside analogues as cytosolic 5â€²-nucleotidase II potential inhibitors: Synthesis, inâ€²vitro evaluation and molecular modeling studies. <i>European Journal of Medicinal Chemistry</i> , 2014, 77, 18-37. | 2.6 | 21 |
| 159 | Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue. <i>International Journal of Cancer</i> , 2003, 107, 149-154. | 2.3 | 20 |
| 160 | Determination of the enzymatic activity of cytosolic 5â€²-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 5747-5758. | 1.9 | 20 |
| 161 | Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosides. <i>Cancer Immunology, Immunotherapy</i> , 1994, 38, 311-316. | 2.0 | 19 |
| 162 | Isoprenoid flavonoids are new leads in the modulation of chemoresistance. <i>Phytochemistry Reviews</i> , 2002, 1, 325-332. | 3.1 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. <i>British Journal of Haematology</i> , 2012, 158, 805-809. | 1.2 | 19 |
| 164 | Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents. <i>PLoS ONE</i> , 2015, 10, e0134247. | 1.1 | 19 |
| 165 | Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). <i>Oncotarget</i> , 2016, 7, 2889-2909. | 0.8 | 19 |
| 166 | Silicosis due to inhalation of domestic cleaning powder. <i>Lancet</i> , The, 1991, 338, 1085. | 6.3 | 18 |
| 167 | Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). <i>Leukemia and Lymphoma</i> , 2005, 46, 335-346. | 0.6 | 18 |
| 168 | High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 54-59. | 1.2 | 18 |
| 169 | Inhibition of IGF-1 Signalling Enhances the Apoptotic Effect of AS602868, an IKK2 Inhibitor, in Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2011, 6, e22641. | 1.1 | 18 |
| 170 | Identification of Noncompetitive Inhibitors of Cytosolic 5â€²-Nucleotidase II Using a Fragment-Based Approach. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9680-9696. | 2.9 | 18 |
| 171 | Kinetics and organ distribution of [14C]-sialic acid-GM3 and [3H]-sphingosine-GM1 after intravenous injection in rats. <i>Biochemical and Biophysical Research Communications</i> , 1992, 189, 1410-1416. | 1.0 | 17 |
| 172 | Doxorubicin Delivery into Tumor Cells by Stable Cavitation without Contrast Agents. <i>Molecular Pharmaceutics</i> , 2017, 14, 441-447. | 2.3 | 17 |
| 173 | Cytosolic 5â€²-Nucleotidase II Interacts with the Leucin Rich Repeat of NLR Family Member Ipaf. <i>PLoS ONE</i> , 2015, 10, e0121525. | 1.1 | 17 |
| 174 | Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. <i>Oncotarget</i> , 2018, 9, 21141-21155. | 0.8 | 17 |
| 175 | Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. <i>Anticancer Research</i> , 2008, 28, 1161-7. | 0.5 | 17 |
| 176 | Benign recurrent cholestasis with normal gamma-glutamyl-transpeptidase activity. <i>Journal of Pediatrics</i> , 1992, 121, 78-80. | 0.9 | 16 |
| 177 | Beta-tubulin III expression in prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010, 44, 371-377. | 1.4 | 16 |
| 178 | Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?. <i>Biomarkers in Medicine</i> , 2013, 7, 663-671. | 0.6 | 16 |
| 179 | Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 855-862. | 0.6 | 16 |
| 180 | The druggability of intracellular nucleotide-degrading enzymes. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 883-893. | 1.1 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Modeling the Colchicum autumnale Tubulin and a Comparison of Its Interaction with Colchicine to Human Tubulin. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1676. | 1.8 | 16 |
| 182 | A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048. | 0.8 | 16 |
| 183 | Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia. <i>Cancer Letters</i> , 2007, 250, 117-127. | 3.2 | 15 |
| 184 | Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review). <i>International Journal of Oncology</i> , 2011, 40, 625-38. | 1.4 | 14 |
| 185 | Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors. <i>Clinical Cancer Research</i> , 2013, 19, 3556-3566. | 3.2 | 14 |
| 186 | 2-[18F]Fludarabine, a Novel Positron Emission Tomography (PET) Tracer for Imaging Lymphoma: a Micro-PET Study in Murine Models. <i>Molecular Imaging and Biology</i> , 2014, 16, 118-126. | 1.3 | 14 |
| 187 | Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e204-e206. | 1.7 | 14 |
| 188 | Beta-hydroxyphosphonate ribonucleoside analogues derived from 4-substituted-1,2,3-triazoles as IMP/GMP mimics: synthesis and biological evaluation. <i>Beilstein Journal of Organic Chemistry</i> , 2016, 12, 1476-1486. | 1.3 | 14 |
| 189 | F-ara-AMP is a substrate of cytoplasmic 5 α -nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2006, 25, 289-297. | 0.4 | 13 |
| 190 | Ungueotropic T-Cell Lymphoma. <i>Archives of Dermatology</i> , 2006, 142, 1065. | 1.7 | 13 |
| 191 | Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. <i>British Journal of Haematology</i> , 2012, 157, 331-338. | 1.2 | 13 |
| 192 | Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674. | 1.1 | 13 |
| 193 | The cytosolic 5 α -nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 67380-67393. | 0.8 | 13 |
| 194 | Multidrug Resistance ABC Transporter Structure Predictions by Homology Modeling Approaches. <i>Current Drug Metabolism</i> , 2011, 12, 268-277. | 0.7 | 13 |
| 195 | Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 661-665. | 0.9 | 13 |
| 196 | Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5700-5703. | 1.0 | 12 |
| 197 | Bortezomib influences the expression of malignant plasma cells membrane antigens. <i>European Journal of Pharmacology</i> , 2013, 706, 11-16. | 1.7 | 12 |
| 198 | Synthesis of New Steroidal Inhibitors of P-Glycoprotein-Mediated Multidrug Resistance and Biological Evaluation on K562/R7 Erythroleukemia Cells. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1832-1845. | 2.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | The genomic landscape of plasma cells in systemic light chain amyloidosis. <i>Blood</i> , 2018, 132, 2775-2777. | 0.6 | 12 |
| 200 | Common Resistance Mechanisms to Nucleoside Analogues in Variants of the Human Erythroleukemic Line K562. <i>Advances in Experimental Medicine and Biology</i> , 1999, 457, 571-577. | 0.8 | 12 |
| 201 | Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma. <i>The Hematology Journal</i> , 2004, 5, 403-409. | 2.0 | 11 |
| 202 | Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. <i>Clinical Leukemia</i> , 2008, 2, 198-204. | 0.2 | 11 |
| 203 | Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2'-deoxyuridine-5'-monophosphate on ABCC11 in silico models. <i>BMC Structural Biology</i> , 2013, 13, 7. | 2.3 | 11 |
| 204 | Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. <i>Leukemia and Lymphoma</i> , 2014, 55, 188-190. | 0.6 | 11 |
| 205 | Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMENSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559. | 1.6 | 11 |
| 206 | Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1238-1247. | 1.9 | 11 |
| 207 | Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length. <i>Transfusion</i> , 2018, 58, 2635-2644. | 0.8 | 11 |
| 208 | Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMENSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811. | 0.6 | 11 |
| 209 | Transient Acute Myopia Induced by Antilymphocyte Globulins. <i>Ophthalmologica</i> , 1999, 213, 133-134. | 1.0 | 10 |
| 210 | A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. <i>International Journal of Cancer</i> , 2006, 119, 60-66. | 2.3 | 10 |
| 211 | Silencing of <i>Tubulin Binding Cofactor C</i> Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 303-312. | 1.9 | 10 |
| 212 | Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74. | 2.8 | 10 |
| 213 | Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice. <i>Journal of Immunological Methods</i> , 1997, 206, 115-123. | 0.6 | 9 |
| 214 | Leukocytosis and Circulating Blasts in Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Are They Valuable Factors for Therapeutic Decision-Making?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 342-349. | 0.2 | 9 |
| 215 | Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. <i>Oncology Reports</i> , 2011, 25, 1161-7. | 1.2 | 9 |
| 216 | Higher percentage of CD34 + CD38 ⁺ cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 622-629. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Deoxycholic acid derivatives as inhibitors of P-glycoprotein-mediated multidrug efflux. <i>Steroids</i> , 2016, 116, 5-12. | 0.8 | 9 |
| 218 | Lead optimization and biological evaluation of fragment-based cN-II inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 168, 28-44. | 2.6 | 9 |
| 219 | Characterization of Tamoxifen-resistant breast cancer cells. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00617. | 1.1 | 9 |
| 220 | IL-3 increases marrow and peripheral erythroid precursors in chronic pure red cell aplasia presenting in childhood. <i>British Journal of Haematology</i> , 1995, 89, 413-416. | 1.2 | 8 |
| 221 | Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. <i>Annals of Oncology</i> , 2003, 14, 615-622. | 0.6 | 8 |
| 222 | Progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological evaluation. <i>Steroids</i> , 2012, 77, 1177-1191. | 0.8 | 8 |
| 223 | Synthesis and Evaluation of a Molecularly Imprinted Polymer for Selective Solid-Phase Extraction of Irinotecan from Human Serum Samples. <i>Journal of Functional Biomaterials</i> , 2012, 3, 131-142. | 1.8 | 8 |
| 224 | Identification of miRNAs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534. | 2.3 | 8 |
| 225 | Functions of the multi-interacting protein KIDINS220/ARMS in cancer and other pathologies. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 114-122. | 1.5 | 8 |
| 226 | Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. <i>Pharmacology</i> , 2018, 102, 161-168. | 0.9 | 8 |
| 227 | Real life management of patients hospitalized with multiple myeloma in France. <i>PLoS ONE</i> , 2018, 13, e0196596. | 1.1 | 8 |
| 228 | Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice. <i>Blood</i> , 2008, 112, 1585-1585. | 0.6 | 8 |
| 229 | 5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine. <i>Haematologica</i> , 2004, 89, 617-9. | 1.7 | 8 |
| 230 | Minimally differentiated acute myeloid leukemia (FAB AML-M0): Prognostic factors and treatment effects on survival: A retrospective study of 42 adult cases. <i>Leukemia Research</i> , 2011, 35, 1027-1031. | 0.4 | 7 |
| 231 | Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 817-824. | 0.9 | 7 |
| 232 | Stably transfected adherent cancer cell models with decreased expression of 5'-nucleotidase cN-II. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2016, 35, 604-612. | 0.4 | 7 |
| 233 | Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents. <i>Journal of Visualized Experiments</i> , 2016, , e53846. | 0.2 | 7 |
| 234 | Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 259-267. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Human T-cell leukemia virus type I-induced proliferation of human thymocytes requires the presence of a comitogen. <i>Cellular Immunology</i> , 1988, 112, 391-401. | 1.4 | 6 |
| 236 | Inclusion complexes of a nucleotide analogue with hydroxypropyl-beta-cyclodextrin. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2009, 63, 11-16. | 1.6 | 6 |
| 237 | Design, synthesis and evaluation of progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3165-3168. | 1.0 | 6 |
| 238 | MRP8/ABCC11 Expression Is Regulated by Dexamethasone in Breast Cancer Cells and Is Associated to Progesterone Receptor Status in Breast Tumors. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-6. | 0.6 | 6 |
| 239 | In vitro antileukaemic activity of extracts from <i>Daphne gnidium</i> leaves against sensitive and multidrug resistant K562/R7 cells. <i>Tumor Biology</i> , 2014, 35, 8991-8998. | 0.8 | 6 |
| 240 | TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2017, 56, 21-28. | 0.4 | 6 |
| 241 | Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. <i>PLoS ONE</i> , 2015, 10, e0136505. | 1.1 | 6 |
| 242 | Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMENSE consortium. <i>Journal of Human Genetics</i> , 2013, 58, 155-159. | 1.1 | 5 |
| 243 | Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1053, 101-110. | 1.2 | 5 |
| 244 | Enhanced migration of breast and lung cancer cells deficient for cN-II and CD73 via COX-2/PGE2/AKT axis regulation. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 151-165. | 2.1 | 5 |
| 245 | A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479. | 1.4 | 5 |
| 246 | Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 97-105. | 1.1 | 4 |
| 247 | A label-free mass spectrometry method for relative quantitation of β -tubulin isotype expression in human tumor tissue. <i>Proteomics - Clinical Applications</i> , 2012, 6, 502-506. | 0.8 | 4 |
| 248 | Granulocyte Colony-Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part I): Synthesis and Biodistribution Studies. <i>Bioconjugate Chemistry</i> , 2018, 29, 795-803. | 1.8 | 4 |
| 249 | Piperidinyl-embedded chalcones possessing anti PI3K inhibitory properties exhibit anti-atopic properties in preclinical models. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 405-413. | 2.6 | 4 |
| 250 | The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?. <i>Leukemia and Lymphoma</i> , 2019, 60, 2572-2575. | 0.6 | 4 |
| 251 | <i>In vitro</i> modulation of multidrug resistance by pregnane steroids and <i>in vivo</i> inhibition of tumour development by 7 α -OBz-11 β -(R)-OTHP-5 β -pregnenedione in K562/R7 and H295R cell xenografts. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 684-691. | 2.5 | 4 |
| 252 | CD73 and cN-II regulate the cellular response to chemotherapeutic and hypoxic stress in lung adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129842. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Proof of Concept: Protein Delivery into Human Erythrocytes Using Stable Cavitation. <i>Molecular Pharmaceutics</i> , 2022, 19, 929-935. | 2.3 | 4 |
| 254 | Reply to "Clinical and therapeutic implications of <i>BRAF</i> mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 498-500. | 1.5 | 3 |
| 255 | Granulocyte-Colony Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part II): Dose-Dependent Biodistribution and <i>In Vivo</i> Antitumor Efficacy in Combination with Rituximab. <i>Bioconjugate Chemistry</i> , 2018, 29, 804-812. | 1.8 | 3 |
| 256 | Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2371-2381. | 1.9 | 3 |
| 257 | Common gene variants within 3' untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021, 148, 1887-1894. | 2.3 | 3 |
| 258 | Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336. | 2.3 | 3 |
| 259 | A Two-complementary Method Assay for Screening New Reversal Agents of Cancer Cell Multidrug Resistance. <i>Pharmaceutical Biology</i> , 2003, 41, 72-77. | 1.3 | 2 |
| 260 | Bacterial Deoxyribonucleoside Kinases are Poor Suicide Genes in Mammalian Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2009, 28, 1068-1075. | 0.4 | 2 |
| 261 | Preparation, Characterization and <i>In Vitro</i> Evaluation of a New Nucleotide Analogue Prodrug Cyclodextrin Inclusion Complexes. <i>Journal of Nanoscience and Nanotechnology</i> , 2009, 9, 295-300. | 0.9 | 2 |
| 262 | Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. <i>Human Molecular Genetics</i> , 2021, 30, 1142-1153. | 1.4 | 2 |
| 263 | Transcriptional and Metabolic Investigation in 5'-Nucleotidase Deficient Cancer Cell Lines. <i>Cells</i> , 2021, 10, 2918. | 1.8 | 2 |
| 264 | Targeting the nucleotide metabolism proteins of the NUDIX family and SAMHD1 in cancer. <i>Current Medicinal Chemistry</i> , 2020, 28, 4088-4116. | 1.2 | 2 |
| 265 | Reply to R.S. Mehta et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 3068-3069. | 0.8 | 1 |
| 266 | Recent Advances in the Discovery of Flavonoids and Analogues with High Affinity Binding to Glycoprotein Responsible for Cancer Cell Multidrug Resistance. <i>ChemInform</i> , 2002, 33, 257-257. | 0.1 | 1 |
| 267 | Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia. <i>Leukemia and Lymphoma</i> , 2021, , 1-6. | 0.6 | 1 |
| 268 | A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. <i>Bulletin Du Cancer</i> , 2006, 93, E115-8. | 0.6 | 1 |
| 269 | Unusual Organisms in the Bone Marrow of a Patient With Systemic Sarcoidosis. <i>Laboratory Medicine</i> , 2005, 36, 762-763. | 0.8 | 0 |
| 270 | Reply to L.C. Panasci. <i>Journal of Clinical Oncology</i> , 2009, 27, e112-e113. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Les anticorps thérapeutiques bispécifiques : deux fois plus puissants ?. Bulletin Du Cancer, 2011, 98, 1381-1382. | 0.6 | 0 |
| 272 | Le microbiome intestinal influence-t-il le développement des hépatocarcinomes ?. Bulletin Du Cancer, 2012, 99, 1105-1106. | 0.6 | 0 |
| 273 | Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 1-24. | 0.1 | 0 |